Show simple item record

dc.contributor.authorFisher, Amy
dc.contributor.authorLanigan, Michael
dc.contributor.authorUpton, Neil
dc.contributor.authorLione, Lisa
dc.date.accessioned2021-02-08T19:15:02Z
dc.date.available2021-02-08T19:15:02Z
dc.date.issued2021-02-08
dc.identifier.citationFisher , A , Lanigan , M , Upton , N & Lione , L 2021 , ' Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research : Translatable and Bidirectional Research ' , Frontiers in Pharmacology , vol. 11 , 614990 . https://doi.org/10.3389/fphar.2020.614990
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/2299/23873
dc.description© 2021 Fisher, Lanigan, Upton and Lione. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). https://creativecommons.org/licenses/by/4.0/
dc.description.abstractFor patients suffering with chronic neuropathic pain the need for suitable novel therapies is imperative. Over recent years a contributing factor for the lack of development of new analgesics for neuropathic pain has been the mismatch of primary neuropathic pain assessment endpoints in preclinical vs. clinical trials. Despite continuous forward translation failures across diverse mechanisms, reflexive quantitative sensory testing remains the primary assessment endpoint for neuropathic pain and analgesia in animals. Restricting preclinical evaluation of pain and analgesia to exclusively reflexive outcomes is over simplified and can be argued not clinically relevant due to the continued lack of forward translation and failures in the clinic. The key to developing new analgesic treatments for neuropathic pain therefore lies in the development of clinically relevant endpoints that can translate preclinical animal results to human clinical trials. In this review we discuss this mismatch of primary neuropathic pain assessment endpoints, together with clinical and preclinical evidence that supports how bidirectional research is helping to validate new clinically relevant neuropathic pain assessment endpoints. Ethological behavioral endpoints such as burrowing and facial grimacing and objective measures such as electroencephalography provide improved translatability potential together with currently used quantitative sensory testing endpoints. By tailoring objective and subjective measures of neuropathic pain the translatability of new medicines for patients suffering with neuropathic pain will hopefully be improved.en
dc.format.extent21
dc.format.extent1976524
dc.language.isoeng
dc.relation.ispartofFrontiers in Pharmacology
dc.subjectNeuropathic pain
dc.subjectTranslatability
dc.subjectPreclinical
dc.subjectClinical
dc.subjectBurrowing
dc.subjectElectroencephalography
dc.subjectQuantitative sensory testing
dc.subjectelectroencephalography
dc.subjectendpoints
dc.subjectclinical
dc.subjectneuropathic pain
dc.subjectpreclinical
dc.subjectburrowing
dc.subjecttranslatability
dc.subjectquantitative sensory testing
dc.subjectPharmacology (medical)
dc.subjectPharmacology
dc.titlePreclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research : Translatable and Bidirectional Researchen
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionTRP Ion channels
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Research in Mechanisms of Disease and Drug Discovery
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85101215936&partnerID=8YFLogxK
rioxxterms.versionofrecord10.3389/fphar.2020.614990
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record